Main efficacy and clinical indications of daprodustat

Daprodustat (Daprodustat) is a new oral drug specifically used to treat anemia in chronic kidney disease. It belongs to the HIF-PHI class of drugs, which promotes the stability of hypoxia-inducible factor (HIF) by inhibiting prolyl hydroxylase in the body, thereby enhancing the secretion of endogenous erythropoietin (EPO). This mechanism is different from traditional exogenous EPO injection preparations, allowing patients to improve hematopoietic function through oral administration and reduce dependence on injections.

The main function of this drug is to effectively increase hemoglobin levels and improve anemia symptoms caused by insufficient red blood cell production in patients with chronic kidney disease. Long-term anemia can cause clinical manifestations such as fatigue, shortness of breath, decreased exercise tolerance, and even affect heart function. The application goal of daprostat is to maintain a relatively stable hemoglobin level by regulating the body's oxygen sensing pathway and help patients restore their daily activities.

In terms of clinical indications, daplestat has been approved overseas for use in adults who have been undergoing dialysis for at least four months. Due to long-term impairment of kidney function, such patients are unable to synthesize sufficient erythropoietin, resulting in anemia that is difficult to correct. Compared with traditional injectable drugs, oral small molecule drugs have better compliance, are easier for patients to accept, and reduce the inconvenience and potential complications associated with injections.

Overseas studies have shown that daprostat is stable in improving anemia in dialysis patients and also has potential application value in some non-dialysis patients with chronic kidney disease. Although it is not currently on the market in China, with the gradual popularity of HIF-PHI drugs, it is expected to change the treatment pattern of anemia in chronic kidney disease together with similar drugs. In the future, daplestat may be explored in more indications, including patients with chronic kidney disease at different stages, thereby providing more treatment options for this population.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat